JOHNSON & JOHNSON (JNJ.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:JNJ • US4781601046

202.05 EUR
+0.15 (+0.07%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, JNJ scores 5 out of 10 in our fundamental rating. JNJ was compared to 55 industry peers in the Pharmaceuticals industry. JNJ has only an average score on both its financial health and profitability. While showing a medium growth rate, JNJ is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • JNJ had positive earnings in the past year.
  • In the past year JNJ had a positive cash flow from operations.
  • JNJ had positive earnings in each of the past 5 years.
  • Of the past 5 years JNJ 4 years had a positive operating cash flow.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • JNJ's Return On Assets of 13.03% is fine compared to the rest of the industry. JNJ outperforms 78.18% of its industry peers.
  • With a decent Return On Equity value of 31.69%, JNJ is doing good in the industry, outperforming 70.91% of the companies in the same industry.
  • JNJ has a Return On Invested Capital of 14.16%. This is in the better half of the industry: JNJ outperforms 69.09% of its industry peers.
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROIC 14.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • JNJ's Profit Margin of 27.26% is amongst the best of the industry. JNJ outperforms 83.64% of its industry peers.
  • JNJ's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.00%, JNJ is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
  • In the last couple of years the Operating Margin of JNJ has grown nicely.
  • Looking at the Gross Margin, with a value of 68.14%, JNJ is doing worse than 60.00% of the companies in the same industry.
  • JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27%
PM (TTM) 27.26%
GM 68.14%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), JNJ is creating some value.
  • There is no outstanding debt for JNJ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.17 indicates that JNJ is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.17, JNJ is doing good in the industry, outperforming 69.09% of the companies in the same industry.
  • The Debt to FCF ratio of JNJ is 2.34, which is a good value as it means it would take JNJ, 2.34 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of JNJ (2.34) is better than 81.82% of its industry peers.
  • JNJ has a Debt/Equity ratio of 0.55. This is a neutral value indicating JNJ is somewhat dependend on debt financing.
  • JNJ has a Debt to Equity ratio (0.55) which is comparable to the rest of the industry.
  • Although JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Altman-Z 5.17
ROIC/WACC1.45
WACC9.75%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

  • JNJ has a Current Ratio of 1.07. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
  • JNJ has a Current ratio of 1.07. This is in the lower half of the industry: JNJ underperforms 70.91% of its industry peers.
  • A Quick Ratio of 0.80 indicates that JNJ may have some problems paying its short term obligations.
  • JNJ has a worse Quick ratio (0.80) than 65.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.8
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • JNJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
  • JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.11% yearly.
  • Looking at the last year, JNJ shows a small growth in Revenue. The Revenue has grown by 6.05% in the last year.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • Based on estimates for the next years, JNJ will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.17% on average per year.
  • The Revenue is expected to grow by 5.37% on average over the next years.
EPS Next Y7.03%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
EPS Next 5Y8.17%
Revenue Next Year6.76%
Revenue Next 2Y6.06%
Revenue Next 3Y6.02%
Revenue Next 5Y5.37%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 22.08, which indicates a rather expensive current valuation of JNJ.
  • JNJ's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 27.92. JNJ is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 20.62 indicates a rather expensive valuation of JNJ.
  • JNJ's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. JNJ is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 22.08
Fwd PE 20.62
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
  • JNJ's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 29.31
EV/EBITDA 18.18
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates JNJ does not grow enough to justify the current Price/Earnings ratio.
  • JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.14
PEG (5Y)3.62
EPS Next 2Y7.63%
EPS Next 3Y7.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • JNJ has a Yearly Dividend Yield of 2.19%.
  • Compared to an average industry Dividend Yield of 1.95, JNJ has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.83, JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.19%

5.2 History

  • On average, the dividend of JNJ grows each year by 9.24%, which is quite nice.
Dividend Growth(5Y)9.24%
Div Incr Years6
Div Non Decr Years6
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 48.70% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
  • The dividend of JNJ is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP48.7%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

JOHNSON & JOHNSON

FRA:JNJ (2/6/2026, 7:00:00 PM)

202.05

+0.15 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap486.80B
Revenue(TTM)94.19B
Net Income(TTM)25.12B
Analysts75
Price Target197.22 (-2.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.19%
Yearly Dividend4.16
Dividend Growth(5Y)9.24%
DP48.7%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.42%
Min EPS beat(2)0.55%
Max EPS beat(2)2.3%
EPS beat(4)4
Avg EPS beat(4)2.37%
Min EPS beat(4)0.55%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.79%
EPS beat(12)11
Avg EPS beat(12)3.6%
EPS beat(16)14
Avg EPS beat(16)3.08%
Revenue beat(2)2
Avg Revenue beat(2)1.48%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.34%
Revenue beat(12)7
Avg Revenue beat(12)-2.01%
Revenue beat(16)7
Avg Revenue beat(16)-8.34%
PT rev (1m)-0.6%
PT rev (3m)4.2%
EPS NQ rev (1m)-3.57%
EPS NQ rev (3m)-3.62%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)1.37%
Revenue NY rev (3m)1.37%
Valuation
Industry RankSector Rank
PE 22.08
Fwd PE 20.62
P/S 6.23
P/FCF 29.31
P/OCF 23.73
P/B 7.24
P/tB N/A
EV/EBITDA 18.18
EPS(TTM)9.15
EY4.53%
EPS(NY)9.8
Fwd EY4.85%
FCF(TTM)6.89
FCFY3.41%
OCF(TTM)8.52
OCFY4.21%
SpS32.42
BVpS27.89
TBVpS-6.16
PEG (NY)3.14
PEG (5Y)3.62
Graham Number75.78
Profitability
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROCE 17.53%
ROIC 14.16%
ROICexc 16.21%
ROICexgc 66.83%
OM 27%
PM (TTM) 27.26%
GM 68.14%
FCFM 21.27%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Debt/EBITDA 1.36
Cap/Depr 62.36%
Cap/Sales 5%
Interest Coverage 250
Cash Conversion 75.02%
Profit Quality 78.02%
Current Ratio 1.07
Quick Ratio 0.8
Altman-Z 5.17
F-Score4
WACC9.75%
ROIC/WACC1.45
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.03%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
EPS Next 5Y8.17%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year6.76%
Revenue Next 2Y6.06%
Revenue Next 3Y6.02%
Revenue Next 5Y5.37%
EBIT growth 1Y2.89%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.35%
EBIT Next 3Y11.24%
EBIT Next 5Y7.6%
FCF growth 1Y-5.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.75%
OCF growth 3YN/A
OCF growth 5YN/A

JOHNSON & JOHNSON / JNJ.DE FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


What is the profitability of JNJ stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for JNJ stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


Is the dividend of JOHNSON & JOHNSON sustainable?

The dividend rating of JOHNSON & JOHNSON (JNJ.DE) is 4 / 10 and the dividend payout ratio is 48.7%.